Europe Non-Invasive Prenatal Testing (NIPT) Market, By Country, Competition, Forecast and Opportunities, 2020-2030F

The Europe Non-Invasive Prenatal Testing (NIPT) Market was valued at USD 0.87 Billion in 2024, and is expected to reach USD 1.91 Billion by 2030, rising at a CAGR of 14.06%. The market is witnessing strong growth driven by heightened awareness of genetic disorders and the rising demand for safer prenatal screening options. With maternal age steadily increasing across Europe, the risk of chromosomal abnormalities is also rising, prompting more expectant mothers to choose non-invasive alternatives to traditional procedures like amniocentesis. NIPT offers accurate results through a simple blood test, eliminating the risk of miscarriage and improving patient compliance. Supportive government policies, expanded private healthcare access, and advancements in genomic technologies are facilitating market expansion. The use of AI for test interpretation and the trend toward personalized medicine are broadening the scope of NIPT, while multiplex assay development and partnerships between diagnostics companies and healthcare providers are streamlining service delivery and improving accessibility.

Key Market Drivers

Rising Maternal Age and Associated Risk of Chromosomal Abnormalities

The growing maternal age across Europe significantly drives demand in the Non-Invasive Prenatal Testing (NIPT) market. As more women delay childbirth due to career, financial, and lifestyle choices, the likelihood of chromosomal disorders like Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13) increases. According to the Office for National Statistics (ONS), the average age of mothers in England and Wales rose to 30.9 years in 2023.

This demographic trend directly correlates with greater use of NIPT, which is non-invasive, highly accurate, and free of the miscarriage risks posed by conventional methods such as amniocentesis or chorionic villus sampling (CVS). NIPT uses maternal blood samples to analyze cell-free fetal DNA, providing a safe and reliable alternative for prenatal screening. In the UK, the National Health Service (NHS) has integrated NIPT into standard prenatal care, improving accessibility. As the average maternal age continues to rise across Europe, demand for accurate, non-invasive screening methods like NIPT is expected to grow substantially, reinforcing its role in modern prenatal care.

Key Market Challenges

High Cost of NIPT

The elevated cost of non-invasive prenatal testing (NIPT) remains a key barrier to widespread adoption across Europe. Advanced technologies such as next-generation sequencing and the need for specialized lab infrastructure contribute to the high per-test expense. In many countries, public healthcare systems do not fully reimburse NIPT, placing the financial burden on patients. This results in limited access for individuals from lower and middle-income groups, restricting overall market penetration.

Additionally, pricing inconsistencies and variable insurance coverage create further challenges for both patients and providers. The cost factor also affects healthcare professionals’ willingness to recommend NIPT and poses budget constraints for broader inclusion in public prenatal screening programs. For diagnostic firms, high operational and production expenses constrain market entry and expansion opportunities. Addressing these financial challenges will require expanded insurance support, government funding, and cost-efficient technological advancements to ensure equitable access to NIPT across the region.

Key Market Trends

Integration of NIPT into Routine Prenatal Care

One of the most significant trends in the European NIPT market is its growing incorporation into routine prenatal care. Advancements in genomics and the shift toward personalized medicine are making NIPT a standard first-line screening method. The test’s accuracy in identifying common chromosomal abnormalities - along with its safety and non-invasive nature - has led healthcare providers to recommend it earlier in pregnancy. National healthcare programs in countries like Belgium and the Netherlands now offer government-funded NIPT to all pregnant women, resulting in high adoption rates.

For instance, second-line NIPT uptake in regions like Andalucía, Spain has reached over 93% for eligible cases. Integration into care protocols enhances patient awareness and enables informed decision-making during early antenatal visits. Additionally, user-friendly platforms and automated analysis tools are improving operational efficiency for clinicians. This mainstreaming of NIPT is paving the way for broader utilization and supporting the transition to comprehensive, individualized prenatal care across Europe.

Key Market Players

F. Hoffmann-La Roche Ltd.
Eurofins LifeCodexx GmbH
Yourgene Health plc
Centogene N.V.
QIAGEN N.V.
Eluthia GmbH
Life Genomics AB
TATAA Biocenter AB
Genoma SA
Synlab International GmbH

Report Scope:

In this report, the Europe Non-Invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Europe Non-Invasive Prenatal Testing (NIPT) Market, By Product:

Consumables
Instruments

Europe Non-Invasive Prenatal Testing (NIPT) Market, By Test Type:

Materni 21
Harmony
Panaroma
Verifi
NIFTY
Others

Europe Non-Invasive Prenatal Testing (NIPT) Market, By Application:

Trisomy
Microdeletion Syndrome
Others

Europe Non-Invasive Prenatal Testing (NIPT) Market, By End User:

Diagnostic Laboratories
Hospitals
Others